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ORIGINAL ARTICLE
Medullary thyroid carcinoma (MTC) is a rare
malignant thyroid tumor that arises from thy-
roid calcitonin-secreting C cells, and accounts for
5–10% of all thyroid cancers. Around 25% of MTC
cases are hereditary.1 Usually, MTC is the earlier
clinical phenotype and the most common cause 
of death in multiple endocrine neoplasia type 2
(MEN 2). The subtype, MEN 2A accounts for
> 80% of all MEN 2. The clinical features of MEN
2A include MTC, pheochromocytoma (50%), and
parathyroid hyperplasia or adenoma (20–30%).
MEN 2B is associated with early aggressive behav-
ior of MTC, characterized by mucosal neuromas,
intestinal ganglioneuromatosis and marfanoid
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Background/Purpose: Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant cancer pre-
disposition syndrome, and > 95% of MEN 2 patients carry rearranged during transfection (RET) proto-
oncogene mutants. We aimed to elucidate the genotype and phenotype relationship of RET proto-oncogene
mutations in Taiwanese subjects with medullary thyroid cancer (MTC).
Methods: We genotyped the MEN-2-associated germ-line mutations by PCR-based sequencing of the RET
gene. DNA was extracted from a total of 69 members from eight unrelated families with individuals affected
by MTC, and from seven sporadic cases of MTC.
Results: RET mutations were found in four MEN 2A families, all at codon 634 (one with C > R, two with
C > F, and one with C > W). One MEN 2A patient carried a de novo mutation at codon 634 (C > R). In two
families of MEN 2B, all carried the mutation at codon 918 (M>T). These two cases of MEN 2B were all de novo
mutations. One family of familial MTC or unclassified MEN 2 carried the codon 620 (C > F) mutation.
Among the seven sporadic cases of MTC, none was found to carry any mutation in hotspot exons. Only two
non-synonymous variants (T278N/exon 4 and D489N/exon 7) were found in two cases. However, these
two variants were not uncommon in our elderly population.
Conclusion: We found that all eight MTC patients with a family history or with the other phenotypes of
MEN 2 had RET mutations, whereas no significant RET mutation was found in seven patients with isolated
MTC without family history and other endocrine diseases. Molecular scanning of the RET gene in MEN 2
and MTC in Taiwanese patients probably should be limited to exons 10, 11 and 16, initially to be cost-
effective. [J Formos Med Assoc 2009;108(5):402–408]
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habitus. Approximately half of the MEN 2B cases
develop pheochromocytoma but not hyperpara-
thyroidism. Familial MTC (FMTC) accounts for
5–15% of patients who suffer from MTC alone
without other endocrine manifestations.2–4
MEN 2 is an autosomal dominant cancer pre-
disposition syndrome that has been described for
over 100 years.5 More than 90% of MEN 2 carri-
ers eventually develop MTC. MEN 2 can be classi-
fied into three major subtypes: MEN 2A, MEN 2B
and FMTC, depending on the occurrence of tissue-
specific endocrine tumors, characteristic features
and the number of affected family members.6,7
MEN 2 is caused by mutations in the RET
(REarranged during Transfection) proto-oncogene.
More than 95% of MEN 2 patients carry RET muta-
tions. The RET proto-oncogene is located on chro-
mosome 10q11.2 and comprises 21 exons, and
encodes a trans-membrane tyrosine kinase recep-
tor. It is involved in the ligand-mediated RET 
signaling pathway of the glial cell line-derived
neurotrophic factor family in neural crest tis-
sues.8–10 RET mutation is found in approximately
one per 30,000 in the population.2 Over 90% of
MEN 2A and FMTC families have missense muta-
tions in one of the six conserved cysteine residues
at codons 609, 611, 618, 620 (in exon 10), 630 or
634 (in exon 11) in the extracellular cysteine-rich
region. Among these cysteine codons, the most
frequent mutation is at codon 634 (63–87%),
particularly with C634R and C634Y (50%) in
MEN 2A. All mutations are thought to induce
ligand-independent constitutive activation of the
receptor and subsequent signaling. Approximately
95% of the MEN 2B patients carry the M918T
(exon 16) missense mutation, whereas the others
harbor a mutation at codon 883 (exon 15) in the
tyrosine kinase domain. These may interfere with
ATP binding, and therefore alter the substrate speci-
ficity of the RET substrate-recognition pocket of the
catalytic core, which leads to ligand-independent
activation or modification of kinase activity.11–16
The aim of this study was to elucidate the RET
mutations in Taiwanese subjects with MTC, and




We recruited 69 members from eight unrelated
families with individuals affected by MTC, and
seven cases of sporadic MTC. The diagnostic cri-
teria of MTC were confirmed by documented his-
topathology. Some of the index cases had been
reported previously.17–19 The control group con-
sisted of 109 elderly people without a history of
thyroid cancer (53 women, 56 men; mean age,
73.1 ± 10.0 years). Informed consent was obtained
from all participants or their legal guardians. The
study was approved by the Human Research Ethics
Committee of the National Taiwan University
Hospital.
DNA sequencing and genotyping
Genomic DNA was extracted from peripheral
blood leukocytes using the Puregene DNA Puri-
fication Kit (Gentra Systems, Minneapolis, MN,
USA), according to the manufacturer’s protocol.
PCR amplification of the 20 exons of the RET gene
was performed. Since exon 21 and parts of exon
20 were not translated, they were not included.
Information on the primers and PCR protocols
are as reported, with some modifications,17,20–22
and are available upon request. The PCR prod-
ucts were purified and sequenced using the ABI
PRISM® BigDye™ Terminator Cycles Sequencing
Kit and were analyzed by an ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). Exons 8, 10, 11 and 13–16 were se-
quenced in both directions. The sequences were
compared with RET sequence data from NCBI
Blast Human database (http://www.ncbi.nlm.nih.
gov/BLAST/). If there was any uncertainty in the
sequence data, they were inspected visually by
two investigators. An independent genomic DNA
sample from peripheral blood or buccal mucosa
was obtained from any subjects who were found
to carry a mutation in the first test. A second test
was performed to confirm the presence of the
mutations.
Furthermore, genomic DNA was obtained as
a control population from 109 unrelated elderly
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subjects without MTC, to check the allele frequen-
cy of T278N and D489N. The PCR products un-
derwent one additional denaturation step at 94°C
for 5 minutes, followed by ramping to 25°C over
70 minutes to allow the formation of homo- or
heteroduplexes, before being subjected to dena-
turing HPLC (DHPLC) analysis. DHPLC was 
performed on the WAVE DNA fragment analysis
system equipped with a DNASep column that used
a UV-C scanner to detect eluted DNA (Trans-
genomic, Crewe, UK), as described previously.23
DNA sequencing performed on PCR products
showed unidentifiable mobility and conforma-
tional change on the chromatogram.
Results
This series is the largest genetic study of MTC pa-
tients in Taiwan. There were 69 subjects from eight
unrelated Taiwanese families with MTC, and seven
sporadic cases of MTC. They were tested for MEN-
2-associated mutations by PCR-based sequencing
of the RET gene exons 8, 10, 11 and 13–16, for
which, hotspot mutations have been documented.
RET mutations were found in four MEN 2A fam-
ilies (A–D), all at codon 634 (one with C > R, two
with C > F, and one with C > W; Table 1). One 
23-year-old woman (family H), initially classified
as sporadic MTC, was lost to follow-up. According
to her mother, she received adrenalectomy a few
years before in the USA. Therefore, she should
probably be reclassified as MEN 2A. This is a 
de novo mutation of codon 634 (C>R). In two fam-
ilies with MEN 2B (F and G), all carried a mutation
at codon 918 (M > T; Table 1). Interestingly, these
two cases of MEN 2B both had de novo mutations.
The mutation was not detected in their parents or
siblings. In family E, there were two family mem-
bers with MTC and three asymptomatic gene carri-
ers (aged < 50 years) who had not yet manifested
other endocrine disorders (Table 1). The patients
were categorized as FMTC or unclassified MEN 2,
based on rigorous criteria,2,6 and persistent follow-
up will be needed to evaluate the risk of pheochro-
mocytoma. In this family, a mutation was found at
codon 620 (C > F). All of the mutations were het-
erozygous and the characteristics of the families
are summarized in Table 1.
Among the seven sporadic cases of MTC, none
was found to carry any mutation after examining
the seven exons that harbored the hotspots. 
We further extended the sequence analysis to the
entire RET coding region beyond the hotspot re-
gions in the remaining seven subjects. We found
five exonic single nucleotide polymorphisms
(SNPs) (A45A/exon 2, A432A/exon 7, P679P/
exon 11, L769L/exon 13, and S904S/exon 15)






Base Amino acid No. of available
than MTC
diagnosis
substitution change carriers members
[Ref.]
A MEN 2A Hyperparathyroidism 27 634 TGCCGC CysArg 3 17 [18]
Pheochromocytoma
B MEN 2A Pheochromocytoma 30 634 TGCTTC CysPhe 3 5 [17]
C MEN 2A Pheochromocytoma 36 634 TGCTTC CysPhe 12 18 [18]
D MEN 2A Pheochromocytoma 36 634 TGCTGG CysTrp 4 5
E FMTC/ Nil 40 620 TGCTTC CysPhe 5 8
unclassified
F MEN 2B Mucosal neuroma 15 918 ATGACG MetThr 1 5 [19]
G MEN 2B Mucosal neuroma 12 918 ATGACG MetThr 1 6
H MEN 2A? Pheochromocytoma* 23 634 TGCCGC CysArg 1 5 [17]
*This sporadic MTC patient was lost to follow-up, and the information was provided by her mother.
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and two non-synonymous variants (T278N/exon
4 in case 7 and D489N/exon 7 in case 3) (Table 2).
Interestingly, these two non-synonymous vari-
ants, T278N in exon 4 (rs35118262) and D489N
in exon 7 (rs9282834), had variable allele frequ-
encies in different populations. By DHPLC ana-
lysis, we found the allele frequencies of these 
two SNPs were 0.037 and 0.037 in 109 elderly
Taiwanese subjects without a history of thyroid
cancer. Therefore, they do not seem to be poten-
tial genetic modifiers. All of the intronic SNPs
have been documented in the Ensembl data base
(Table 2).
Discussion
The EUROMEN Study Group found an age-
dependent progression of early MTC depending
on the specific RET codon. In subjects with codon
634 mutants, the mean age at diagnosis was 10
years, the average interval from tumor develop-
ment to nodal metastasis was 6.6 years, and the
cumulative risk rose steadily from 14 years of age
onwards.11,24 Skinner et al provided at least 5
years of follow-up data to suggest that an MEN 2A
asymptomatic carrier who underwent total thy-
roidectomy before 8 years of age could be cured.25
The consensus of the 7th International MEN
Workshop advocated stratification of the medical
management of hereditary MTC into three levels
according to gene-based information. Level 3
(highest risk): children with MEN 2B or RET codon
883, 918, or 922 mutation have the most aggres-
sive MTC and should undergo prophylactic thy-
roidectomy within the first 6 months, preferably
within the first month of life. Level 2 (high risk):
children with any RET codon 609, 611, 618, 620,
630, or 634 mutation should undergo thyroidec-
tomy by age 5 years. Level 1 (least high risk): chil-
dren with RET codon 768, 790, 791, 804, and 891
mutations may be operated on later, or opt for pe-
riodic pentagastrin-stimulated calcitonin testing.
Nevertheless, the recommendations about central
lymph node dissection at initial thyroidectomy are
controversial, and a more individualized approach
may be needed among the MEN 2 variants.6,26
This recommendation highlights the need for
Table 2.. RET gene polymorphisms in seven sporadic cases of medullary thyroid cancer
Case no.
Exonic SNP Intronic SNP
Codon/exon* SNP ID: Allele*
1 A45A/exon 2, A432A/exon 7, L769L/exon 13 rs35906041: CC > –, rs2742243: T > C, rs3026750: G > A,
rs34827976: C >, rs2472737: G > A, rs17028: C > T
2 A45A/exon 2, A432A/exon 7, L769L/exon 13, rs35906041: CC > –, rs2742243: T > C, rs3026750: G > A, 
S904S/exon 15 rs34827976: C > –
3 A45A/exon 2, A432A; D489N/exon 7, L769L/exon 13 rs12246855: A > G, rs12246856: A/C, rs35906041: CC > –, 
rs2742243: T > C, rs3026750: G > A, rs34827976: C > –, 
rs2472737: G > A, rs17028: C > T
4 A45A/exon 2, A432A/exon 7, L769L/exon 13 rs2742243: T > C, rs3026750: G > A, rs34827976: C > –, 
rs2472737: G > A, rs17028: C > T
5 A45A/exon 2, A432A/exon 7, P679P/exon 11, rs10900296: A > G, rs10900297: C > A, rs12267460: G > A, 
L769L/exon 13, S904S/exon 15 rs2435351: G > A, rs35906041: CC > –, rs2742243: T > C, 
rs3026750: G > A, rs34827976: C > –, rs2472737: G > A, 
rs17028: C > T
6 A432A/exon 7 Nil
7 A45A/exon 2, T278N/exon 4†, rs2435351: G > A, rs35906041: CC > –, rs2742243: T > C, 
A432A/exon 7, L769L/exon 13, S904S/exon 15 rs3026750: G > A, rs34827976: C > –, rs2472737: G > A, 
rs17028: C > T
*Based on the Ensembl Genome Browser Human CCDS7200; †extracted from http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=5979.
DNA-based testing and effective clinical inter-
vention for possible cure of MEN 2 carriers. For
routine genetic testing, recent consensus guide-
lines suggest that only a limited number of mu-
tations, which involve RET exons 10, 11 and
13–16, should be analyzed, and these account
for >95% of MEN 2 carriers.6 Some studies have
shown more complex genetic variations, with
high incidence (10–40%) occurring throughout
the RET gene outside the hotspot exons.27,28
However, the clinical significance of some of the
novel variants remains uncertain.29
In this study, we found that all eight MTC pa-
tients with a family history or other characteristic
features of MEN 2 had RET germ-line mutations.
Moreover, all of the mutations in our hereditary
MEN 2A/FMTC cases were confined to exon 10 or
11 of the RET extracellular cysteine-rich region.
Two MEN 2B had codon 918 mutations. Among
the seven isolated MTC patients without family
history and other endocrine disorders, we did not
identify any mutation in hotspot exons or any
significant mutations in the exons, other than the
hotspots reported previously.8,30 Furthermore,
we found two non-synonymous variants, T278N
(rs35118262) and D489N (rs9282834), in two
cases of sporadic MTC. Their allele frequencies
were approximately 4% in Taiwanese elderly sub-
jects without a history of thyroid cancer, and there-
fore, did not appear to play a role in MTC. Our
findings suggest that, in Taiwanese patients with
MTC, the mutation spectrum of the RET proto-
oncogene is limited. For subjects with MEN 2A or
FMTC, molecular scanning of exons 10 and 11 is
essential and probably adequate. For MEN 2B, ex-
amination of exon 16 is essential and probably
adequate. Based on our data, these investigations
should be cost-effective. If no mutation is found,
the search probably can be extended to the other
hotspot exons and beyond. For sporadic MTC
without family history or other endocrine disor-
ders, molecular scanning of exon 11 is essential
and probably adequate. However, this and further
searches in hotspot exons and beyond may not
be fruitful, according to our results. The present
survey coincides with previous studies in other
Asian countries.31–34 Consistent with the current
consensus guidelines, molecular scanning for MTC,
with or without MEN manifestations and family
history, should be limited to exons 10, 11 and 16,
and then extended to the other hotspot exons if
necessary. Although comprehensive sequencing of
genome is feasible technically, it may not be finan-
cially cost-effective to extend the search for muta-
tions beyond these regions.
Specific RET mutations in patients with MEN 2
have been shown to predict the phenotypic ex-
pression of the disease and MTC aggressiveness,
and therefore, to provide prognostic information
to guide prophylactic thyroidectomy and screen-
ing for pheochromocytoma.26,35,36 This is espe-
cially valuable in children and young adults.37,38
However, the current recommendations are all
based on observations in Caucasian populations.
Since the genetic background of Asian popula-
tions is different, the natural course of various
RET mutant carriers may be different.31,33,39–42
Our clinical observations showed that long-term
survival was not uncommon with a persistent and
indolent course of hereditary MTC, even in the
absence of systemic treatment. Some of the MEN
2A cases had been followed regularly for >10 years
and had persistent hypercalcitoninemia. One man
died of sepsis and acute renal failure aged 71 years,
and one woman died of pneumonia aged 46 years.
None of the other family members directly died
of MTC. More data from our own population are
required before an evidence-based recommenda-
tion can be implemented. The age of onset for the
mutation at codon 918 appears to be earlier than
for mutations at the other codons. Our case num-
ber is still too small to correlate the clinical course
with the genetic test results. Nevertheless, inter-
national guidelines should be used before that.
At present, cancer-prevention strategies for
mutant gene carriers involve the prenatal diagnosis
or preimplantation genetic diagnosis and assisted
reproductive techniques to prevent recurrence of
the mutant gene in future generations. This offers
families another choice to fight against this no-
torious hereditary disease, especially for those
who are stratified into the level 3 (highest risk)
C.F. Chang, et al
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genotype.43,44 MEN 2 provides a fascinating exam-
ple for early prevention and cure of cancer. It also
provides important insight into the psychosocial
issues and genetic counseling in cancer therapy.
We propose that, for the subjects with manifesta-
tions of MEN 2A or FMTC, exons 10 and 11 should
be examined first. For those with manifestations
of MEN 2B, exon 16 should be examined first.
For sporadic MTC without family history and
other endocrine disorders, sequencing exon 11
should be carried out first.
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